Table 6 Diagnostic power of IGF2 to discriminate patients with HCC from patients with cirrhosis in different three staging systems
Classification | AUC | Sens% | Spe% | PPV% | NPV% | AC% |
|---|---|---|---|---|---|---|
Number of nodules (n, %) | ||||||
Single (67, 43.2%) | 0.90 | 88 | 73.3 | 67 | 92 | 80 |
Multiple (88, 56.8) | 0.86 | 79 | 73.3 | 73 | 82 | 78 |
Macrovascular invasion (n, %) | ||||||
Absent (141, 91%) | 0.88 | 83 | 73.3 | 81 | 79 | 80 |
Present (14, 9%) | 0.88 | 80 | 73.3 | 36 | 96 | 77 |
Size of nodules (n, %) | ||||||
<2 (48, 31%) | 0.85 | 75 | 73.3 | 56 | 89 | 76 |
>2 (107, 69%) | 0.89 | 86 | 73.3 | 77 | 85 | 81 |
BCLC stage (n, %) | ||||||
0-A (109, 70.3%) | 0.88 | 77 | 73.3 | 77 | 79 | 77 |
B (46, 29.7) | 0.88 | 79 | 73.3 | 77 | 88 | 77 |
CLIP stage (n, %) | ||||||
0-1 (122, 79%) | 0.88 | 84 | 73.3 | 77 | 82 | 80 |
2-3 (33, 21%) | 0.89 | 78 | 73.3 | 77 | 92 | 77 |
Okuda stage (n, %) | ||||||
Stage I (117, 75.5%) | 0.89 | 87 | 73.3 | 79 | 85 | 82 |
Stage II (38, 24.5%) | 0.89 | 79 | 73.3 | 61 | 89 | 77 |